Phase II study of dolastatin-10 in patients with hormone-refractory metastatic prostate adenocarcinoma

U. Vaishampayan, M. Glode, W. Du, Andrew Kraft, G. Hudes, J. Wright, M. Hussain

Research output: Contribution to journalArticle

124 Citations (Scopus)

Abstract

Dolastatin-10 is a natural, cytotoxic peptide with microtubule-inhibitory and apoptotic effects. It has demonstrated in vitro and in vivo efficacy in the DU-145 human prostate cancer model. A Phase II clinical trial was designed in patients with hormone-refractory prostate cancer. Dolastatin-10 was administered at a dose of 400 μg/m2 i.v. every 3 weeks. Dose escalation to 450 μg/m2 was permitted. Toxicity evaluation was conducted every 2 weeks, and assessment of response was done at the end of every two cycles. Sixteen patients were enrolled between October 1998 to December 1999. The median age was 71 years (range, 59-79 years). Median prostate-specific antigen value was 108 ng/ml (range, 15.3-1672 ng/ml). Of the 15 eligible patients, 7 were Caucasian and 8 were African-American. Eight patients had bone-only metastases, and seven had measurable disease with or without bone metastases. A total of 56 cycles have been administered. Only 2 patients required dose adjustment because of toxicity, and in 5 patients, dose escalation was feasible to 450 μg/m2. The major toxicities observed were grade 3 and 4 neutropenia in 8 patients and grade 3 neuropathy in 1 patient. All 15 patients are evaluable for response. Three patients demonstrated stable disease; 2 of these had bone disease, and 1 had nodal metastasis. All others had disease progression. Dolastatin-10 is very well tolerated in this elderly, pretreated population but lacks significant clinical activity as a single agent.

Original languageEnglish (US)
Pages (from-to)4205-4208
Number of pages4
JournalClinical Cancer Research
Volume6
Issue number11
StatePublished - 2000
Externally publishedYes

Fingerprint

dolastatin 10
Prostate
Adenocarcinoma
Hormones
Neoplasm Metastasis
Prostatic Neoplasms
Bone and Bones
Phase II Clinical Trials

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Vaishampayan, U., Glode, M., Du, W., Kraft, A., Hudes, G., Wright, J., & Hussain, M. (2000). Phase II study of dolastatin-10 in patients with hormone-refractory metastatic prostate adenocarcinoma. Clinical Cancer Research, 6(11), 4205-4208.

Phase II study of dolastatin-10 in patients with hormone-refractory metastatic prostate adenocarcinoma. / Vaishampayan, U.; Glode, M.; Du, W.; Kraft, Andrew; Hudes, G.; Wright, J.; Hussain, M.

In: Clinical Cancer Research, Vol. 6, No. 11, 2000, p. 4205-4208.

Research output: Contribution to journalArticle

Vaishampayan, U, Glode, M, Du, W, Kraft, A, Hudes, G, Wright, J & Hussain, M 2000, 'Phase II study of dolastatin-10 in patients with hormone-refractory metastatic prostate adenocarcinoma', Clinical Cancer Research, vol. 6, no. 11, pp. 4205-4208.
Vaishampayan, U. ; Glode, M. ; Du, W. ; Kraft, Andrew ; Hudes, G. ; Wright, J. ; Hussain, M. / Phase II study of dolastatin-10 in patients with hormone-refractory metastatic prostate adenocarcinoma. In: Clinical Cancer Research. 2000 ; Vol. 6, No. 11. pp. 4205-4208.
@article{23ff12d59e1f43f088eed1249a67b171,
title = "Phase II study of dolastatin-10 in patients with hormone-refractory metastatic prostate adenocarcinoma",
abstract = "Dolastatin-10 is a natural, cytotoxic peptide with microtubule-inhibitory and apoptotic effects. It has demonstrated in vitro and in vivo efficacy in the DU-145 human prostate cancer model. A Phase II clinical trial was designed in patients with hormone-refractory prostate cancer. Dolastatin-10 was administered at a dose of 400 μg/m2 i.v. every 3 weeks. Dose escalation to 450 μg/m2 was permitted. Toxicity evaluation was conducted every 2 weeks, and assessment of response was done at the end of every two cycles. Sixteen patients were enrolled between October 1998 to December 1999. The median age was 71 years (range, 59-79 years). Median prostate-specific antigen value was 108 ng/ml (range, 15.3-1672 ng/ml). Of the 15 eligible patients, 7 were Caucasian and 8 were African-American. Eight patients had bone-only metastases, and seven had measurable disease with or without bone metastases. A total of 56 cycles have been administered. Only 2 patients required dose adjustment because of toxicity, and in 5 patients, dose escalation was feasible to 450 μg/m2. The major toxicities observed were grade 3 and 4 neutropenia in 8 patients and grade 3 neuropathy in 1 patient. All 15 patients are evaluable for response. Three patients demonstrated stable disease; 2 of these had bone disease, and 1 had nodal metastasis. All others had disease progression. Dolastatin-10 is very well tolerated in this elderly, pretreated population but lacks significant clinical activity as a single agent.",
author = "U. Vaishampayan and M. Glode and W. Du and Andrew Kraft and G. Hudes and J. Wright and M. Hussain",
year = "2000",
language = "English (US)",
volume = "6",
pages = "4205--4208",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "11",

}

TY - JOUR

T1 - Phase II study of dolastatin-10 in patients with hormone-refractory metastatic prostate adenocarcinoma

AU - Vaishampayan, U.

AU - Glode, M.

AU - Du, W.

AU - Kraft, Andrew

AU - Hudes, G.

AU - Wright, J.

AU - Hussain, M.

PY - 2000

Y1 - 2000

N2 - Dolastatin-10 is a natural, cytotoxic peptide with microtubule-inhibitory and apoptotic effects. It has demonstrated in vitro and in vivo efficacy in the DU-145 human prostate cancer model. A Phase II clinical trial was designed in patients with hormone-refractory prostate cancer. Dolastatin-10 was administered at a dose of 400 μg/m2 i.v. every 3 weeks. Dose escalation to 450 μg/m2 was permitted. Toxicity evaluation was conducted every 2 weeks, and assessment of response was done at the end of every two cycles. Sixteen patients were enrolled between October 1998 to December 1999. The median age was 71 years (range, 59-79 years). Median prostate-specific antigen value was 108 ng/ml (range, 15.3-1672 ng/ml). Of the 15 eligible patients, 7 were Caucasian and 8 were African-American. Eight patients had bone-only metastases, and seven had measurable disease with or without bone metastases. A total of 56 cycles have been administered. Only 2 patients required dose adjustment because of toxicity, and in 5 patients, dose escalation was feasible to 450 μg/m2. The major toxicities observed were grade 3 and 4 neutropenia in 8 patients and grade 3 neuropathy in 1 patient. All 15 patients are evaluable for response. Three patients demonstrated stable disease; 2 of these had bone disease, and 1 had nodal metastasis. All others had disease progression. Dolastatin-10 is very well tolerated in this elderly, pretreated population but lacks significant clinical activity as a single agent.

AB - Dolastatin-10 is a natural, cytotoxic peptide with microtubule-inhibitory and apoptotic effects. It has demonstrated in vitro and in vivo efficacy in the DU-145 human prostate cancer model. A Phase II clinical trial was designed in patients with hormone-refractory prostate cancer. Dolastatin-10 was administered at a dose of 400 μg/m2 i.v. every 3 weeks. Dose escalation to 450 μg/m2 was permitted. Toxicity evaluation was conducted every 2 weeks, and assessment of response was done at the end of every two cycles. Sixteen patients were enrolled between October 1998 to December 1999. The median age was 71 years (range, 59-79 years). Median prostate-specific antigen value was 108 ng/ml (range, 15.3-1672 ng/ml). Of the 15 eligible patients, 7 were Caucasian and 8 were African-American. Eight patients had bone-only metastases, and seven had measurable disease with or without bone metastases. A total of 56 cycles have been administered. Only 2 patients required dose adjustment because of toxicity, and in 5 patients, dose escalation was feasible to 450 μg/m2. The major toxicities observed were grade 3 and 4 neutropenia in 8 patients and grade 3 neuropathy in 1 patient. All 15 patients are evaluable for response. Three patients demonstrated stable disease; 2 of these had bone disease, and 1 had nodal metastasis. All others had disease progression. Dolastatin-10 is very well tolerated in this elderly, pretreated population but lacks significant clinical activity as a single agent.

UR - http://www.scopus.com/inward/record.url?scp=0033739893&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033739893&partnerID=8YFLogxK

M3 - Article

C2 - 11106233

AN - SCOPUS:0033739893

VL - 6

SP - 4205

EP - 4208

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 11

ER -